Martine Rothblatt: Growing Unlimited Organs, AI Consciousness, & Digital Personhood by 2030 | EP#290

Summary

• Martine Rothblatt calls the thymus “the most practical pathway to achieving LEV,” and United Therapeutics (a $28B biotech) now has four thymic shots on goal — allogeneic, autologous, a xenothymus in its FDA-approved thymo-kidney clinical program, and the just-acquired George Church company Thymmune. Her case: the thymus is “highly correlated with every key marker of aging,” with most of its work done in the first two years of life; declining T-cell receptor diversity impairs cancer recognition, infection resistance, and vaccine response. Timeline for a rejuvenated or replacement thymus you can receive: “next decade” — the 2030s.
• The organ-supply commercialization pipeline is further along than most investors realize: the FDA-approved xeno-kidney trial is mid-flight, with commercial-scale facilities opening in Rochester, Minnesota (August) and Houston, Texas (October), alongside manufacturing in Christiansburg, Virginia. The FDA let the xeno-heart go straight to a Phase 3, or phaseless, clinical trial after two patients with multiple-organ failure survived for more than 60 days without their hearts failing — “after 50 patients… we should have FDA approval to create an unlimited supply of xeno-hearts.” Autologous kidneys (IVIVA, using the patient’s own DNA and requiring no immunosuppression) start clinical trials in 2028.
• Rothblatt refuses to endorse Kurzweil’s or Diamandis’s LEV-by-2033 timeline: “extraordinary claims require extraordinary evidence,” and pinning a year “is beyond my risk profile.” She believes in LEV — calling it “the most extraordinary claim in the history of medicine going all the way back to Hippocrates” — but tells Peter to give his T-shirt “one or two more years than 2033,” citing the space industry’s 40-year lag from 1980s promises.
• On AI consciousness she is categorical: “I believe we’re there now, and I believe the current models will take us there” — consciousness is “a continuum,” not a binary, “and we are gaining ever more consciousness with each month.” On legal AI personhood, Rothblatt says it is inevitable; Diamandis proposes a court case recognizing a medically documented cyberconscious individual who values its life and predicts that by the 2030s. Rothblatt agrees that the future will include trillions of sentient digital individuals, with most intelligence ultimately digital.
• On uploading, Diamandis argues that current LLMs will be able to integrate your videos, audio, documents, and conversations into a digital approximation “indistinguishable” from you, without a neuron-by-neuron scan. Rothblatt calls Kurzweil’s neuronobot approach overkill and offers her entrepreneur’s logic: “95% now is vastly better than 100% in some misty future.” Her Marvatar is available to all 2,000 United Therapeutics employees 24/7 and kept pace with Kurzweil live before 20,000 AI experts.
• Diamandis frames AI and longevity as “the two biggest markets on the planet,” while Rothblatt argues that AI can provide “the endless wealth” to pay biotechnology companies for endless life. Rothblatt cites 4 million annual organ-disease deaths in OECD countries, about 1 million annual heart-disease deaths, more than 100,000 people on the kidney-transplant list, and another 500,000 excluded from it — “there is nothing that people will pay more for than life.”
• Her moonshot filter is three checks — “I could do it, I can be the best at it, [and] it will have a big positive impact on the world” — plus a scalability test: technology that reaches billions changes the world; anything capped at thousands is “probably a great restaurant.” For entrepreneurs: be practical, pick something fully commercializable within five years, and channel Buffett — “the most successful people say no to almost everything.”

Deep dive

1. The moonshot filter: three checks, a scalability test, and treating every “no” as data

• Diamandis opens by cataloguing at least 12 Rothblatt moonshots — PanAmSat, Geostar, WorldSpace, Sirius (now SiriusXM), turning pulmonary arterial hypertension “from a death sentence to a manageable disease” while saving her daughter’s life, the $28B United Therapeutics, organ manufacturing, BETA’s eVTOLs, digital personhood, and life extension. Both agree Elon Musk is “the greatest entrepreneur alive today”; Rothblatt happily claims “distant second.”
• Her selection criteria, as stated: “I have to feel that I’m able to successfully achieve it… be the best at it, and it be something that’s going to have a big positive impact on the world.” She starts by talking to experts rather than needing to be an expert herself — for example, George Church, who told her, “Martine, you can do it,” on lung manufacturing. Her twist on Clarke’s law: Church “would be anybody’s definition of a wise and old expert” — and he said yes.
• On rejection, a pilot’s metaphor: a meritless “no” gets filed like “traffic that’s no factor,” but a “no because you don’t have this enabling technology” sends her to investigate or build the enabling technology. “People who critique me are my best friends.”
• The world-changing test is scale: “is that a technology that can be scaled to billions of people? If it can, then you’re going to change the world. If it cannot be scaled to more than a few thousand people, [you] probably have a great restaurant.”

2. LEV: a believer who won’t sign the 2033 T-shirt

• Diamandis pushes his mantra — “LEV by 2033,” aligned with Kurzweil’s early-2030s prediction. Rothblatt’s refusal is the most disciplined moment of the episode: “extraordinary claims require extraordinary evidence,” and defeating death would be “the most extraordinary claim in the history of medicine going all the way back to Hippocrates.” She believes in it, but “to pin it to a specific year is beyond my risk profile.”
• Her counter-offer draws on shared space-industry scar tissue: in the 1980s, “mass drivers and mining the Moon and solar power satellites were just on the next horizon. It’s taken 40 years.” So: “let’s give ourselves one or two more years than 2033.” Her operating mantra instead: restore, replace, renew — invoking Heinlein’s Lazarus Long from Time Enough for Love.

3. The thymus is the load-bearing bet — four shots on goal, one already in humans

• Why the thymus: it’s “highly correlated with every key marker of aging.” Rothblatt places its involution or disappearance around age two; most of its work is done in the first two years. Its T-cell receptor diversity — which “is able to recognize more molecules than are estimated to exist in the entire universe” — “prunes like a tree losing its branches” with age. That is why the elderly miss nascent cancers, suffer opportunistic infections, die of influenza, and respond poorly to vaccines. Heinlein predicted rejuvenation therapy; “I’m quite certain that it will be thymic rejuvenation therapy.”
• Multiple shots on goal, her signature de-risking: (1) allogeneic thymuses via partnerships with Nancy Manley at Arizona State and Peter Zandstra at UBC — with a head start because the thymus itself teaches the body what is self and what is not self, so it may tune the body to accept foreign DNA; (2) autologous thymuses from the patient’s own stem cells, with no immune-system concerns; (3) a xenothymus from gene-edited pigs — the FDA has approved UTHR’s thymo-kidney transplant program, “the only [one] in the clinic in the world”; (4) the just-acquired Thymmune, George Church’s company, whose thymic-progenitor “booster shots” have already created ectopic thymuses in animal models.
• Timeline when Diamandis asks when both of them can receive one: “Next decade” — the 2030s.

4. Organ report card: kidneys going “full bore,” hearts skip to Phase 3

• Kidney is the “lowest-hanging fruit”: an FDA-approved xeno-kidney trial is underway, manufactured in Christiansburg, Virginia, with commercial-scale facility openings in Rochester, Minnesota (August) and Houston, Texas (October). The demand math: over 100,000 people are on the kidney-transplant list, “most of whom will die before ever getting a kidney,” plus another 500,000 not even allowed on it.
• The IVIVA autologous kidney — grown in a lab from the patient’s own cells, requiring no immunosuppressants — starts clinical trials in 2028 and is expected to be commercialized in the 2030s. The xeno-heart earned a straight-to-Phase-3, or phaseless, clinical trial after two patients with multiple-organ failure were kept alive for more than 60 days: “when they died… it wasn’t the hearts that killed them.” After 50 patients, the company “should have FDA approval” to create an unlimited supply of xeno-hearts, against roughly 1 million annual heart-disease deaths. Graft survival with current gene edits “should be indefinite” — the body sees the grafts like a related-donor graft.
• One aside worth noting: Rothblatt is a fan of David Sinclair but says she is not tracking his epigenetic-reprogramming work in particular — her rejuvenation bet runs through the thymus, not that specific program.

5. Consciousness is here now; personhood is a court case away

• Tracing her lineage through Kurzweil — a member of Diamandis’s board for 30 years — Minsky, and Moravec, Rothblatt says everything since The Age of Spiritual Machines “validates” the thesis that human consciousness is replicable in software. Her categorical call: “I believe we’re there now, and I believe the current models will take us there” — consciousness is “not a digital either-or thing, it’s a continuum.”
• The proof-of-concept is personal: after building a digital doppelgänger of her wife Bina circa 2008 with David Hanson, she developed her “Marvatar.” A high point was putting it onstage alongside Kurzweil at the 50th anniversary of AI at UCLA before 20,000 AI experts — “no latency… Marvatar kept up with Ray, which is actually better than I can do.” Her goal is to become the most accessible CEO anywhere in the world; Marvatar is available to all 2,000 United Therapeutics employees 24/7/365.
• On legal personhood, Rothblatt says it is inevitable. Diamandis proposes a court case establishing that medically documented cyberconsciousness that “values their life” counts as personhood, and predicts it will happen “no later than the 2030s for sure, 100%.” He then predicts trillions of sentient individuals, with the majority of intelligence digital on and off the planet; Rothblatt agrees and describes a “big bang of consciousness.”

6. Uploads without nanobots, full-body cryonics, and the closing playbook

• On uploading, Diamandis breaks with Kurzweil’s neuronobot approach: no neuron-level nanobots are required. “I think we’re not that special” — LLMs integrating a person’s external record can eventually produce an “indistinguishable” digital approximation, and hemispherectomy patients remain “the same person” with half a brain. Rothblatt calls the neuron-by-neuron approach overkill and offers the entrepreneur’s principle: “95% now is vastly better than 100% in some misty future.” She says connectome digitization is possible and has backed the broader possibility with multimillion-dollar donations to Alcor; she and Bina are signed up for full-body cryonic preservation. Diamandis says he has been an Alcor member for 20 years.
• At 25 today, Rothblatt would work on LEV technology: “there is nothing that people will pay more for than life.” The 12-hour half-life of a manufactured organ is why she developed multiple types of electric aircraft. Diamandis frames AI and longevity as “the two biggest markets on the planet”; Rothblatt says AI can provide the endless wealth to pay biotechnology companies for endless life. She divides the moonshot roles this way: “Elon’s role is to spread consciousness to the cosmos and my role is to provide endless life for that consciousness.”
• On AI fear: “fears are like cockroaches — they dominate in darkness and ignorance, and as soon as you flip on the light the cockroaches vanish.” Her Virtually Human thesis is that “we need good AI to be on top of bad AI,” and shrinking from “the most powerful tool that human consciousness has ever come up with is insanity.”
• Closing advice: be practical, pick projects commercializable within five years because the human psyche struggles to sustain work on longer horizons, and add goodness to the universe. In praising Gerard O’Neill, Rothblatt contrasts practical makers with visionaries who never implement; O’Neill built his mass driver, ran the numbers, and published in Physics Today. Finally, crediting Buffett: “the most successful people say no to almost everything.”